Phase 3 N=3,556 Preventing Sexual Transmission of HIV With Anti-HIV Drugs
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 2 N=58 ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
HIV Infections
Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml
N/A N=9 Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV
Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml
N/A N=11 Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
Human Immunodeficiency Virus (HIV)
Primary: Epithelial Disruption Graded by a Pathologist Blinded to Study Intervention. — 1.0; 1.17 units on a scale — p=<0.05
Phase 3 N=1,870 Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
HIV Infections
Primary: Antepartum Component: Number of Confirmed Infant HIV Infections — 25; 7; 2 Participants
Phase 4 N=225 HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
HIV
Primary: Number of Participants With HIV Viral Load Suppression in Plasma — 2; 1; 84; 8 Participants
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 4 N=372 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…
Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Phase 4 N=59 Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk
HIV · Contraception
Primary: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood — 26.6; 22.8; 16.9; 22.4 percentage of HIV target immune cells
N/A N=136 The Risk of HIV Acquisition Among Traditional Healers in South Africa
HIV Infections
Primary: Blood Exposure — 1.9; 1.9 Number of Glove Pairs Used Per Razor Bla
N/A N=1,967 Implementing a Comprehensive Prevention of Mother-to-Child Transmission of HIV Program for South African Couples
HIV · Pregnancy
Primary: Dried Blood Spot Analysis of Medication Adherence- Mother and Infant — 56; 157; 35; 183 Participants
Phase 3 N=654 Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand
Hepatitis B Chronic Infection · Pregnancy
Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants
Phase 3 N=1,522 Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding
HIV Infections
Primary: HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study — 8; 18; 700; 699 participants — p=0.049
Phase 1 N=16 Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults
Human Immunodeficiency Virus Prevention · Human Immunodeficiency Virus (HIV)
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants
Phase 3 N=1,735 Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission
Disease Transmission, Vertical · Vertical Human Immunodeficiency Virus Transmission · HIV Infections
Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046
N/A N=43 Adherence to HIV Treatment Postpartum: The Implications of Transitions Among Women Living With HIV in South Africa
HIV · Pregnancy Related
Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
N/A N=38 Improving HIV Outcomes Among African American Transgender Women
HIV
Primary: Change in Percentage of Participants With HIV Transmission Risk at Month 6 — 23.077; 38.462; 46.154; 46.154 percentage of participants with no risk — p=.19
N/A N=100 HIV Self-testing With Online Supervision for Vietnamese MSM
HIV
Primary: HIV Self-testing With Online Supervision Past 6 Months at Baseline — 50; 44 Participants
N/A N=9,572 HIV Screening in the Emergency Department Setting
HIV Infections
Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 3 N=4,758 Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
HIV-1 Infections · HIV Infections
Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001
N/A N=128 Podcasting HIV Prevention Within African American Communities
HIV Prevention
Primary: Change in Condom Use Self-Efficacy (From Baseline to 1 Month Follow-up) — 4.4 score on a scale — p=<.001
Phase 4 N=1,653 IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
HIV Infection
Primary: Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or Death — 0.21; 0.31 New cases per 100 person - years…